Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease
Introduction Nontuberculous pulmonary disease causes significant morbidity and mortality. Efforts to tackle infections are hampered by the lack of reliable biomarkers for diagnosis, assessment and prognostication. The aim of this study was to develop molecular assays capable of identifying and quant...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-03-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/9/2/00435-2022.full |
| _version_ | 1797809395388645376 |
|---|---|
| author | Huw C. Ellis Miriam F. Moffatt Colin Churchward Leah Cuthbertson William O.C. Cookson Michael R. Loebinger |
| author_facet | Huw C. Ellis Miriam F. Moffatt Colin Churchward Leah Cuthbertson William O.C. Cookson Michael R. Loebinger |
| author_sort | Huw C. Ellis |
| collection | DOAJ |
| description | Introduction
Nontuberculous pulmonary disease causes significant morbidity and mortality. Efforts to tackle infections are hampered by the lack of reliable biomarkers for diagnosis, assessment and prognostication. The aim of this study was to develop molecular assays capable of identifying and quantifying multiple nontuberculous mycobacterial (NTM) species and to examine their utility in following individual patients’ clinical courses.
Methods
DNA was extracted from 410 sputum samples obtained longitudinally from a cohort of 38 patients who were commencing treatment for either Mycobacterium abscessus or Mycobacterium avium complex or who were patients with bronchiectasis who had never had positive cultures for mycobacteria. NTM quantification was performed with quantitative PCR assays developed in-house.
Results
The molecular assays had high in vitro sensitivity and specificity for the detection and accurate quantification of NTM species. The assays successfully identified NTM DNA from human sputum samples (in vivo sensitivity: 0.86–0.87%; specificity: 0.62–0.95%; area under the curve: 0.74–0.92). A notable association between NTM copy number and treatment (Friedman ANOVA (df)=22.8 (3), p≤0.01 for M. abscessus treatment group) was also demonstrated.
Conclusion
The quantitative PCR assays developed in this study provide affordable, real-time and rapid measurement of NTM burden, with significant implications for prompt management decisions. |
| first_indexed | 2024-03-13T06:52:01Z |
| format | Article |
| id | doaj.art-c90a5ac8355443e783003e379a727ec8 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-03-13T06:52:01Z |
| publishDate | 2023-03-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-c90a5ac8355443e783003e379a727ec82023-06-07T13:31:07ZengEuropean Respiratory SocietyERJ Open Research2312-05412023-03-019210.1183/23120541.00435-202200435-2022Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial diseaseHuw C. Ellis0Miriam F. Moffatt1Colin Churchward2Leah Cuthbertson3William O.C. Cookson4Michael R. Loebinger5 Host Defence Unit, Royal Brompton Hospital, London, UK Imperial College London, London, UK Imperial College London, London, UK Imperial College London, London, UK Imperial College London, London, UK Host Defence Unit, Royal Brompton Hospital, London, UK Introduction Nontuberculous pulmonary disease causes significant morbidity and mortality. Efforts to tackle infections are hampered by the lack of reliable biomarkers for diagnosis, assessment and prognostication. The aim of this study was to develop molecular assays capable of identifying and quantifying multiple nontuberculous mycobacterial (NTM) species and to examine their utility in following individual patients’ clinical courses. Methods DNA was extracted from 410 sputum samples obtained longitudinally from a cohort of 38 patients who were commencing treatment for either Mycobacterium abscessus or Mycobacterium avium complex or who were patients with bronchiectasis who had never had positive cultures for mycobacteria. NTM quantification was performed with quantitative PCR assays developed in-house. Results The molecular assays had high in vitro sensitivity and specificity for the detection and accurate quantification of NTM species. The assays successfully identified NTM DNA from human sputum samples (in vivo sensitivity: 0.86–0.87%; specificity: 0.62–0.95%; area under the curve: 0.74–0.92). A notable association between NTM copy number and treatment (Friedman ANOVA (df)=22.8 (3), p≤0.01 for M. abscessus treatment group) was also demonstrated. Conclusion The quantitative PCR assays developed in this study provide affordable, real-time and rapid measurement of NTM burden, with significant implications for prompt management decisions.http://openres.ersjournals.com/content/9/2/00435-2022.full |
| spellingShingle | Huw C. Ellis Miriam F. Moffatt Colin Churchward Leah Cuthbertson William O.C. Cookson Michael R. Loebinger Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease ERJ Open Research |
| title | Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| title_full | Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| title_fullStr | Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| title_full_unstemmed | Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| title_short | Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| title_sort | molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease |
| url | http://openres.ersjournals.com/content/9/2/00435-2022.full |
| work_keys_str_mv | AT huwcellis molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease AT miriamfmoffatt molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease AT colinchurchward molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease AT leahcuthbertson molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease AT williamoccookson molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease AT michaelrloebinger molecularassessmentofmycobacterialburdeninthetreatmentofnontuberculousmycobacterialdisease |